ACADIA Pharmaceuticals Aims for $1.7B in Sales by 2028, Highlights Commercial Growth and Upcoming Readouts

ACADIA Pharmaceuticals aims to reach $1.7B in sales by 2028, driven by commercial momentum from its two marketed products, NUPLAZID and DAYBUE. The company plans to expand its field force, invest in AI, biomarkers, and global expansion, and has outlined clinical milestones across neurology and rare disease. NUPLAZID targets Parkinson's disease psychosis and DAYBUE is the first treatment for Rett syndrome. ACADIA has treated 97,000 patients with NUPLAZID and over 2,000 with DAYBUE, with a 55% retention rate at 12 months.